Intravenous/intramuscular ergot alkaloids vs no uterotonic agents: Use of therapeutic uterotonics
Intravenous/intramuscular ergot alkaloids may leads to lower use of therapeutic uterotonics compared with no uterotonic agents (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Intravenous/intramuscular ergot alkaloids vs no uterotonic agents Use of therapeutic uterotonics · women in the third stage of labour Intravenous/intramuscular ergot alkaloids may leads to lower use of therapeutic uterotonics compared with no uterotonic agents (low certainty). Prophylactic use of ergot alkaloids in the third stage of labour (2018) · Cochrane Headline outcomes only | RR 0.25 [0.1, 0.66] | 2 studies · 2409 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Prophylactic use of ergot alkaloids in the third stage of labour 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.